IO-202 is under clinical development by Immune Onc Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IO-202’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IO-202 overview

IO-202 is under development for the treatment of relapsed or refractory acute myeloid leukemia, chronic myelomonocytic leukemia and solid tumors. The drug candidate acts by targeting LILRB4. It is administered through intravenous route.

Immune Onc Therapeutics overview

Immune Onc Therapeutics (Immune-Onc) is a cancer immunotherapy company. It discovers and develops new immunomodulatory approaches to cancer treatment. The company aims to translate unique scientific insights into the immune suppressive pathways and tumor microenvironment to develop first-in-class biotherapeutics. It identifies and utilizes antibodies targeting an immune inhibitory receptor for the treatment of acute myeloid leukemia (AML) and other cancers. Its pipeline product includes IO-202, for acute myeloid leukemia and other hematologic and solid tumors. Immune-Onc is headquartered in Palo Alto, California, the US.

For a complete picture of IO-202’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.